Skip to main content
Log in

ANCA-GBM Dot-Blot: Evaluation of an Assay in the Differential Diagnosis of Patients Presenting with Rapidly Progressive Glomerulonephritis

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Rapidly progressive glomerulonephritis (RPGN) is characterized by rapid and progressive loss of renal function and the presence of crescentic glomerulonephritis (CGN). Early diagnosis and appropriate treatment is mandatory to prevent death and/or renal failure. We have evaluated an ANCA-GBM dot-blot diagnostic test in terms of sensitivity, specificity, and inter-observer effect in consecutive patients with RPGN (n = 82). Control sera (n = 34) included healthy and relevant disease controls. Dot-blots were independently evaluated by nine observers. Proteinase 3 (PR3)-ANCA, myeloperoxidase (MPO)-ANCA, and both were detected by ELISA in 36, 32, and 3 samples of 71 patients with pauci-immune CGN, respectively. Two additional samples were ANCA negative. The dot-blot revealed a sensitivity of 92–95% for PR3-ANCA and 80–86% for MPO-ANCA. The specificity of the dot-blot for PR3- and MPO-ANCA was 100%. In the patients with anti-GBM nephritis (n = 9) anti-GBM was detected by both ELISA and dot-blot (sensitivity: 100%). The specificity of the anti-GBM dot-blot was 91–94%. However, the inter-observer effect was relatively high for detection of anti-GBM antibodies (24%). In conclusion, the ANCA-GBM dot-blot is a useful screening tool in situations where conventional ANCA testing is not readily available with excellent performance for PR3-ANCA detection, but less optimal sensitivity for MPO-ANCA and specificity for anti-GBM detection. Therefore, it is recommended to include the following advises in the report to the physicians: 1) patients with a high clinical suspicion for MPO-ANCA-associated RPGN and negative dot-blot must have conventional analysis for MPO-ANCA, and 2) negative anti-GBM dot-blot makes anti-GBM disease very unlikely, but positive samples should be confirmed by conventional anti-GBM tests.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Hricik DE, Chung-Park M, Sedor JR: Glomerulonephritis. N Engl J Med 339:888–899, 1998

    PubMed  Google Scholar 

  2. Johnson JP: Rapidly progressive glomerulonephritis. In Primer on kidney disease, A Greenberg (eds). San Diego, Academic Press, 1994, pp. 94–99

    Google Scholar 

  3. Bajema IM, Hagen EC, Hermans J, Noel LH, Waldherr R, Ferrario F, Van Der Woude FJ, Bruijn JA: Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 56:1751–1758, 1999

    PubMed  Google Scholar 

  4. Slot MC, Cohen Tervaert JW, Franssen CF, Stegeman CA: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 63:670–677, 2003

    PubMed  Google Scholar 

  5. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A: Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features. Kidney Int 57:846–862, 2000

    PubMed  Google Scholar 

  6. Cohen Tervaert JW, Limburg PC, Elema JD, Huitema MG, Horst G, The TH, Kallenberg CG: Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med 91:59–66, 1991

    Google Scholar 

  7. Csernok E, Ahlquist D, Ullrich S, Gross WL: Acritical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 41:1313–1317, 2002

    Google Scholar 

  8. Boomsma MM, Stegeman CA, Oost-Kort WW, Kallenberg CG, Moguilevsky N, Limburg PC, Cohen Tervaert JW: Native and recombinant proteins to analyze auto-antibodies to myeloperoxidase in pauciimmune crescentic glomerulonephritis. J Immunol Methods 254:47–58, 2001

    PubMed  Google Scholar 

  9. Jennette JC, Wilkman AS, Falk RJ: Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 135:921–930, 1989

    Google Scholar 

  10. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23–32, 1996

    PubMed  Google Scholar 

  11. Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, The TH, von dem Borne AE, Kallenberg CG: Autoantibodies against myeloid lysosomal en-zymes in crescentic glomerulonephritis. Kidney Int 37:799–806, 1990

    PubMed  Google Scholar 

  12. Glassock RJ, Adler SG, Cohen AH: Primary Glomerular Diseases. In The Kidney (vol 1), BM Brenner, FC Rector (eds). Philadelphia, W.B. Saunders Company, 1991, pp. 1182–1279

    Google Scholar 

  13. Boomsma MM, Damoiseaux JG, Stegeman CA, Kallenberg CG, Patnaik M, Peter JB, Cohen Tervaert JW: Image analysis: A novel approach for the quantification of antineutrophil cytoplasmic anti-body levels in patients with Wegener's granulomatosis. J Immunol Methods 274:27–35, 2003

    PubMed  Google Scholar 

  14. Short AK, Esnault VL, Lockwood CM: Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: Two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis 26:439–445, 1995

    PubMed  Google Scholar 

  15. Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C: Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 8:376–385, 1997

    PubMed  Google Scholar 

  16. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Al-port's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348:2543–2556, 2003

    PubMed  Google Scholar 

  17. Rutgers A, Heeringa P, Damoiseaux J, Cohen Tervaert JW: ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. Eur J Intern Med 14:287–295, 2003

    PubMed  Google Scholar 

  18. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL: Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 63:1079–1085, 2003

    PubMed  Google Scholar 

  19. Stegeman CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 17:2077–2080, 2002

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rutgers, A., Damoiseaux, J., Roozendaal, C. et al. ANCA-GBM Dot-Blot: Evaluation of an Assay in the Differential Diagnosis of Patients Presenting with Rapidly Progressive Glomerulonephritis. J Clin Immunol 24, 435–440 (2004). https://doi.org/10.1023/B:JOCI.0000029115.79266.ae

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOCI.0000029115.79266.ae

Navigation